A detailed history of E Fund Management Co., Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 23,838 shares of BCRX stock, worth $185,459. This represents 0.01% of its overall portfolio holdings.

Number of Shares
23,838
Previous 28,285 15.72%
Holding current value
$185,459
Previous $174,000 4.02%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$6.41 - $8.69 $28,505 - $38,644
-4,447 Reduced 15.72%
23,838 $181,000
Q2 2024

Aug 12, 2024

SELL
$4.13 - $6.79 $189,546 - $311,627
-45,895 Reduced 61.87%
28,285 $174,000
Q1 2024

May 13, 2024

BUY
$4.89 - $7.65 $111,800 - $174,901
22,863 Added 44.55%
74,180 $376,000
Q4 2023

Feb 06, 2024

BUY
$4.98 - $6.77 $48,903 - $66,481
9,820 Added 23.66%
51,317 $307,000
Q3 2023

Nov 13, 2023

SELL
$6.71 - $7.92 $73,313 - $86,533
-10,926 Reduced 20.84%
41,497 $294,000
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $40,632 - $51,432
5,838 Added 12.53%
52,423 $369,000
Q1 2023

May 11, 2023

BUY
$7.94 - $11.84 $50,260 - $74,947
6,330 Added 15.72%
46,585 $389,000
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $50,799 - $68,699
4,838 Added 13.66%
40,255 $462,000
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $97,012 - $133,156
-8,991 Reduced 20.25%
35,417 $446,000
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $219,081 - $496,473
27,767 Added 166.86%
44,408 $470,000
Q1 2022

May 12, 2022

BUY
$11.56 - $19.76 $20,299 - $34,698
1,756 Added 11.8%
16,641 $271,000
Q4 2021

Feb 11, 2022

BUY
$11.18 - $15.46 $39,532 - $54,666
3,536 Added 31.16%
14,885 $206,000
Q3 2021

Nov 12, 2021

BUY
$14.21 - $17.65 $5,385 - $6,689
379 Added 3.45%
11,349 $163,000
Q1 2021

May 12, 2021

BUY
$7.37 - $13.61 $80,848 - $149,301
10,970 New
10,970 $111,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.